Statin-induced Myopathy: Hypothesis About Randomized Evidence and Clinical Impressions

The American Journal of Medicine

Volume 122, Issue 1, January 2009, Pages 4-5

R.C. Pasternak et al.
ACC/AHA/NHLBI Clinical advisory on the use and safety of statins
Circulation
(2002)
C. Baigent et al.
Cholesterol Treatment Trialists' (CTT) CollaboratorsEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins
Lancet
(2005)
J.R. Crouse et al.
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis; The METEOR Trial
JAMA
(2007)

There are more references available in the full text version of this article.

Prescription of Aspirin and Statins in Primary Prevention
2019, Primary Care - Clinics in Office Practice
Citation Excerpt :
In randomized, double-blind, placebo-controlled trials and their meta-analyses, statins are safe and well tolerated.24,30 At present, however, there are large discrepancies between randomized evidence and self-reports by patients of muscle symptoms.33 Claims data, no matter how large, are useful only to formulate, not test hypotheses.
Toxic myopathies
2013, Neuromuscular Disorders in Clinical Practice
Inflammatory and toxic myopathy
2012, Seminars in Neurology
Agents and mechanisms of toxic myopathy
2009, Current Opinion in Neurology

: Conflict of Interest: This article poses no conflicts of interest for the author. The work is original and the author meets the criteria for authorship, including acceptance of responsibility for the scientific content and writing of the article. The author's financial affiliations with all organizations, including any with a financial interest, direct or indirect, in the subject matter or materials discussed in the article that may affect the conduct or reporting of the work submitted are listed below:

: The author serves as an independent scientist in an advisory role to investigators and sponsors, including as Chair or Member on Data and Safety Monitoring Boards, for AstraZeneca, Bristol-Myers Squibb, Food and Drug Administration, Merck, National Association for Continuing Education, National Institutes of Health, Pfizer, PriMed and UpToDate. The author serves on speakers' bureaus for the International Atherosclerosis Society and AstraZeneca, concerning lipids and heart failure, as well as Pfizer, concerning lipids.

: The author receives royalties for authorship or editorship of 3 textbooks.

: The author receives royalties as co-inventor on patents concerning inflammatory markers and cardiovascular disease, which are held by Brigham and Women's Hospital.

: The author has an investment management relationship with SunTrust Bank, who has sole discretionary investment authority.